EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES (EEJMMS)
ISSN: 2992-4103
©EEJMMS Publications Volume 6 Issue 3 2025

Steroid Treatment in Chronic Inflammatory Diseases: Analyzing Effectiveness and Patient Outcomes in Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Asthma

Wambui Kibibi J.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Chronic inflammatory diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Asthma pose significant challenges due to persistent inflammation, tissue damage, and complex management needs. Corticosteroids have long been a cornerstone in the treatment of these conditions, owing to their potent anti-inflammatory and immunosuppressive effects. This review critically examines the effectiveness of steroid therapy in controlling inflammation and improving patient outcomes across these diseases. It highlights the clinical benefits of corticosteroids, including rapid symptom relief and disease modulation, while also addressing the substantial risks associated with long-term use, such as metabolic disturbances, osteoporosis, organ damage, and increased infection susceptibility. Comparative analysis reveals variations in steroid application, dosing strategies, and side effect profiles among RA, SLE, and Asthma patients. Furthermore, the review explores challenges like steroid resistance and underscores the emerging role of steroid-sparing agents, including biologics and immunomodulators, that aim to minimize adverse effects without compromising disease control. Personalized medicine approaches, leveraging biomarkers to optimize treatment regimens, and comprehensive management strategies integrating non-pharmacological interventions are emphasized as key to improving therapeutic outcomes. This synthesis of current evidence informs clinical decision-making and highlights future directions in balancing the therapeutic benefits of corticosteroids with minimizing their risks, ultimately advancing patient care in chronic inflammatory diseases.

Keywords: Corticosteroids, Chronic inflammatory diseases, Rheumatoid arthritis, Asthma, Steroid efficacy.

INTRODUCTION

Chronic inflammatory diseases (CIDs) represent a significant burden on global health systems, affecting millions of individuals and contributing to substantial morbidity and mortality. Among these conditions, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Asthma are particularly prevalent and debilitating [1]. These disorders are characterized by immune system dysregulation, leading to persistent inflammation, tissue damage, and functional impairment. The pathophysiological hallmark of these diseases involves aberrant activation of immune pathways that result in the excessive production of pro-inflammatory cytokines and chemokines [2].

Corticosteroids—synthetic analogs of the endogenous hormone cortisol—have been a cornerstone in the management of chronic inflammatory diseases for decades. These agents exert their effects by binding to glucocorticoid receptors, leading to the suppression of inflammatory gene expression and the enhancement of anti-inflammatory pathways [3]. Their rapid and potent anti-inflammatory properties make them invaluable in the acute management of disease flares and in stabilizing patients with severe inflammation.

In Rheumatoid Arthritis, corticosteroids help reduce joint pain, swelling, and progression of joint destruction. In Systemic Lupus Erythematosus, they are indispensable for controlling systemic manifestations such as nephritis, serositis, and central nervous system involvement. In Asthma, corticosteroids, particularly inhaled corticosteroids (ICS), are the mainstay for reducing airway inflammation, controlling symptoms, and preventing exacerbations [4]. However, despite their well-documented efficacy, the use of corticosteroids is fraught with challenges. Prolonged use is associated with a wide array of adverse effects, including osteoporosis, diabetes, hypertension, cataracts,

adrenal suppression, and increased susceptibility to infections. These complications necessitate a careful risk-benefit analysis, especially in chronic settings where long-term treatment is often unavoidable [5].
Moreover, the variability in patient responses, the potential for steroid resistance, and the emergence of newer biologic therapies have raised critical questions regarding the optimal role of steroids in the contemporary management of chronic inflammatory diseases. There is a growing emphasis on developing treatment strategies that minimize steroid exposure while maintaining disease control [6]. Despite their widespread use and proven efficacy, corticosteroids present a paradox in the management of chronic inflammatory diseases. On one hand, they provide prompt symptom relief and life-saving control of severe inflammation. On the other, their long-term use is linked to serious adverse effects that can significantly impair patient quality of life and complicate disease management [7].

There is limited comprehensive comparative analysis on how corticosteroids perform across different inflammatory conditions such as RA, SLE, and Asthma in terms of patient outcomes, effectiveness, and long-term complications. Furthermore, questions remain about how patient-specific factors such as age, comorbidities, disease severity, and adherence—affect steroid response and outcomes. With the increasing availability of steroid-sparing agents, it is imperative to reevaluate the role of corticosteroids in the current therapeutic landscape [8].
Given the lack of integrated studies evaluating both the benefits and limitations of steroid use across multiple chronic inflammatory diseases, this review seeks to fill that gap by analyzing their therapeutic value, assessing patient outcomes, and providing a balanced perspective on their role in disease management [9]. This review aims to comprehensively analyze the effectiveness and patient outcomes of corticosteroid treatment in managing chronic inflammatory diseases, specifically Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Asthma. It focuses on evaluating how well corticosteroids control inflammation and disease symptoms, examining both short-term and long-term patient outcomes such as quality of life and disease progression. The study also investigates the adverse effects linked to steroid use across these conditions and explores strategies to reduce steroid dependency, including tapering protocols, combination therapies, and the use of biologic agents. Key research questions guide the review, addressing corticosteroid efficacy, common side effects, variations in outcomes depending on dosage, duration, and administration methods, as well as the comparative benefits and limitations of steroids in each disease. Additionally, it seeks to identify best practices for minimizing steroid-related complications while maintaining effective disease control. The significance of this study lies in its potential to improve clinical management and patient care for chronic inflammatory diseases, which contribute substantially to global disability. Given the well-known risks of long-term corticosteroid use, healthcare providers must carefully balance treatment benefits against potential harms. This review synthesizes current evidence to inform clinical decision-making, especially in settings with limited access to newer therapies. Moreover, it emphasizes personalized medicine by considering how individual patient factors influence steroid responsiveness, enabling tailored treatment approaches. Finally, the findings can inform policy development and clinical guidelines, highlighting gaps in current practice and encouraging further research. This contributes to more rational corticosteroid use and supports the advancement of steroid-sparing alternatives, ultimately improving outcomes for patients with RA, SLE, and Asthma.

Mechanism of Action of Steroids

Glucocorticoids exert their therapeutic effects primarily through interaction with intracellular glucocorticoid receptors located within the cytoplasm of target cells. Upon binding to these receptors, the glucocorticoid-receptor complex undergoes a conformational change and translocates into the cell nucleus, where it influences gene transcription [10]. This modulation of gene expression leads to the upregulation of anti-inflammatory proteins and the downregulation of pro-inflammatory mediators. Specifically, glucocorticoids inhibit the production and release of key pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), which play crucial roles in driving inflammation. Additionally, they suppress the movement and activation of leukocytes (white blood cells) to sites of inflammation, thereby reducing immune cell infiltration into affected tissues. One important anti-inflammatory protein whose expression is increased is lipocortin-1 (also known as annexin-1), which further inhibits the activity of phospholipase A2, an enzyme involved in the synthesis of inflammatory mediators like prostaglandins and leukotrienes [11]. Collectively, these actions result in a significant reduction of inflammation and immune responses, making glucocorticoids highly effective in treating a wide range of inflammatory and autoimmune conditions.

Steroid Use in Rheumatoid Arthritis (RA)

Steroid use plays a significant role in the management of rheumatoid arthritis (RA), primarily as a bridging therapy while waiting for disease-modifying antirheumatic drugs (DMARDs) to exert their effects [12]. Corticosteroids, particularly low-dose prednisone at doses of 10 mg per day or less, have demonstrated the ability to reduce joint swelling, alleviate pain, and improve physical function in patients with RA. Clinical trials consistently show that when corticosteroids are used alongside DMARDs, they effectively reduce inflammation and slow the radiographic progression of joint damage, contributing to better disease control. However, the benefits of corticosteroids come

with important limitations. While short-term use can significantly improve symptoms such as joint stiffness and discomfort, prolonged corticosteroid therapy is associated with serious adverse effects including osteoporosis, hypertension, diabetes, and increased susceptibility to infections [13]. To balance these risks, clinicians often employ tapering strategies to gradually reduce corticosteroid doses and use adjunctive treatments like bisphosphonates to protect bone health. Overall, corticosteroids remain an essential component in RA management for rapid symptom relief, but careful monitoring and preventive measures are critical to minimize long-term complications and optimize patient outcomes.

Steroid Use in Systemic Lupus Erythematosus (SLE)

Steroids play a crucial role in the management of Systemic Lupus Erythematosus (SLE), particularly during disease flares and severe organ involvement. Conditions such as lupus nephritis, neuropsychiatric lupus, and hematologic abnormalities often require prompt and aggressive treatment, where corticosteroids become indispensable [14]. In acute and life-threatening situations, high-dose corticosteroids like methylprednisolone pulses are administered to rapidly control inflammation and reduce both mortality and morbidity. After stabilization, maintenance therapy usually involves tapering to lower steroid doses to balance disease control with minimizing side effects. Despite their effectiveness, prolonged steroid use carries significant risks. Chronic exposure to steroids is strongly associated with irreversible organ damage, especially affecting the cardiovascular system and musculoskeletal structures. Research consistently demonstrates that the cumulative steroid dose is a major predictor of long-term damage accrual in SLE patients [15]. Consequently, there is a growing emphasis on steroid-sparing treatment strategies to reduce these adverse effects. Agents such as mycophenolate mofetil and hydroxychloroquine are commonly used alongside steroids to maintain disease remission while minimizing steroid exposure. Overall, while steroids remain a cornerstone in SLE management, careful monitoring and the use of adjunct therapies are essential to optimize patient outcomes and mitigate the risks associated with long-term corticosteroid therapy.

Steroid Use in Asthma

Steroid use plays a crucial role in the management of asthma, with corticosteroids being categorized into inhaled corticosteroids (ICS) and systemic corticosteroids, which include oral and intravenous forms. Inhaled corticosteroids serve as the cornerstone for long-term asthma control due to their effectiveness in reducing airway inflammation, lowering symptom frequency, and decreasing the risk of exacerbations [16]. They are typically prescribed for daily use in patients with persistent asthma to maintain stable respiratory function. On the other hand, systemic corticosteroids are primarily reserved for short-term use during acute exacerbations or in patients with severe asthma phenotypes that do not respond adequately to ICS alone. These systemic steroids provide rapid relief by quickly suppressing widespread inflammation during asthma attacks. However, the use of corticosteroids is not without complications. ICS generally have fewer systemic side effects but can lead to local issues such as oral candidiasis (thrush) and hoarseness, which can be minimized with proper inhaler technique and mouth rinsing. Long-term systemic steroid use poses more serious risks including adrenal suppression, weight gain, osteoporosis, and increased susceptibility to infections. Fortunately, recent advances in biologic therapies, such as anti-IgE and anti-IL-5 agents, have significantly reduced the dependence on systemic steroids in patients with severe asthma, improving overall patient outcomes and minimizing steroid-related adverse effects [17].

Table 1: Comparative Evaluation Across Diseases

Parameter	Rheumatoid Arthritis	Systemic Lupus Erythematosus	Asthma
Common steroid use	Low-dose maintenance	Pulse/high-dose for flares	ICS for control, systemic for exacerbations
Primary benefit	Symptom relief, disease modulation	Life-saving in severe flares	Rapid inflammation control
Long-term risk	Bone loss, CVD, infection	Organ damage, CVD, infection	Adrenal suppression, metabolic syndrome
Use of steroid-sparing agents	Yes (DMARDs)	Yes (immunosuppressants)	Yes (biologics, ICS step-down)

Challenges and Considerations

One of the significant challenges in managing asthma, particularly severe cases, is steroid resistance. This resistance arises primarily due to alterations in glucocorticoid receptor function, which diminishes the therapeutic effectiveness of corticosteroids, the mainstay treatment for inflammation control [18]. When patients exhibit steroid resistance, standard dosages may fail to control symptoms effectively, necessitating alternative or adjunct therapies. In addition

to resistance issues, careful monitoring during steroid therapy is crucial to minimize adverse effects. Prolonged use of corticosteroids can lead to serious side effects, including adrenal insufficiency, osteoporosis, and metabolic disturbances. To mitigate these risks, healthcare providers must implement structured tapering schedules when reducing steroid dosages, ensuring the adrenal glands have time to recover normal function. Equally important is adopting a patient-centered approach in the long-term management of asthma [19]. This means healthcare professionals must consider the individual's overall health, including any comorbid conditions such as diabetes or hypertension, which may be exacerbated by steroid use. Patient preferences and quality of life factors also play a vital role in treatment decisions. Balancing the benefits of steroid therapy against potential risks requires continuous dialogue, personalized assessment, and shared decision-making to optimize outcomes and improve adherence.

Emerging Alternatives and Future Directions

The management of many chronic diseases has seen significant advancements with the increasing use of biologic agents and targeted therapies. These biologics, such as tumor necrosis factor (TNF) inhibitors, B-cell depleting agents, and anti-interleukin (IL)-5 or IL-13 therapies, have revolutionized treatment by directly targeting specific components of the immune system involved in disease processes [20]. Their growing application is helping to reduce the traditional reliance on corticosteroids, which, despite their efficacy, carry substantial risks when used long-term, including immunosuppression and metabolic side effects. Complementing these advances, personalized medicine has emerged as a crucial strategy in optimizing treatment outcomes. By utilizing biomarkers—measurable indicators of disease activity or drug response—clinicians can tailor therapies to individual patients more precisely, thereby enhancing efficacy while minimizing unnecessary steroid exposure and adverse effects. Additionally, non-pharmacological approaches remain essential in comprehensive chronic disease management. Lifestyle modifications such as diet, exercise, and smoking cessation contribute significantly to disease control and overall health [21]. Equally important are patient education and psychosocial support, which empower individuals to manage their conditions more effectively, improve adherence to treatment, and address mental health aspects often associated with chronic illnesses. Together, these multifaceted strategies are transforming patient care by integrating advanced therapies with personalized and holistic support.

CONCLUSION

In conclusion, corticosteroids remain a fundamental component in managing chronic inflammatory diseases such as Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Asthma due to their potent anti-inflammatory effects and rapid symptom relief. However, their long-term use is limited by significant adverse effects, including metabolic complications, organ damage, and increased infection risk. This review highlights the importance of balancing the benefits of steroid therapy with these risks through careful dosing, monitoring, and tapering strategies. The emergence of biologic and targeted therapies has been pivotal in reducing steroid dependency by offering more precise and effective disease control with fewer side effects. Personalized medicine, guided by biomarkers, further enhances treatment optimization by tailoring interventions to individual patient needs. Additionally, non-pharmacological approaches such as lifestyle changes, patient education, and psychosocial support play essential complementary roles in holistic disease management. Overall, integrating advanced therapies with personalized and supportive care offers the best potential to improve patient outcomes, minimize steroid-related harm, and advance the long-term management of chronic inflammatory diseases.

REFERENCES

1. Barber, M.R.W., Drenkard, C., Falasinnu, T., Hoi, A., Mak, A., Kow, N.Y., Svenungsson, E., Peterson, J., Clarke, A.E., Ramsey-Goldman, R.: Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 17, 515–532 (2021). https://doi.org/10.1038/s41584-021-00668-1
2. Bhol, N.K., Bhanjadeo, M.M., Singh, A.K., Dash, U.C., Ojha, R.R., Majhi, S., Duttaroy, A.K., Jena, A.B.: The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomedicine & Pharmacotherapy. 178, 117177 (2024). https://doi.org/10.1016/j.biopha.2024.117177
3. Yasir, M., Goyal, A., Sonthalia, S.: Corticosteroid Adverse Effects. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
4. Ibiam, U. A., Orji, O. U., Aja, P. M., Ezeani, N. N. and Ekpono, E. U. Anti- Inflammatory Effects of Buchholzia coriacea Ethanol Leaf-Extract and Fractions in Freund's Adjuvant-Induced Rheumatoid Arthritic Albino Rats. Indo American Journal of Pharmaceutical Sciences (IAJPS). 2018; 5 (7): 6341- 6357. https://doi.org/10.5281/zenodo.1311167.

5. Téllez Arévalo, A.M., Quaye, A., Rojas-Rodríguez, L.C., Poole, B.D., Baracaldo-Santamaría, D., Tellez Freitas, C.M.: Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. Medicina. 59, 56 (2022). https://doi.org/10.3390/medicina59010056
6. Obasi, N. A., Orji, O. U., Ezeani, N. N., Aja, P. M., Mordi, J. C. et al Effect of ethanol and aqueous extracts of seed pod of Copaifera salikounda (Heckel) on complete Freund's adjuvant-induced rheumatoid arthritis in rats. J Food Biochem. 2019 Jul;43(7):e12912. doi: 10.1111/jfbc.12912. Epub 2019 May 23. PMID: 31353723.
7. Hodgens, A., Sharman, T.: Corticosteroids. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
8. Ibiam, U. A., Ugwuja, E. I., Aja, P. M., Igwenyi, I. O., et al. Antioxidant Effect of Buchholziacoriacea Ethanol Leaf Extract and Fractions on Freund's Adjuvant-induced Arthritis in Albino Rats: A Comparative Study. SlovenianVeterinary Research. 2022; 59 (1): 31–45. doi: 10.26873/svr-1150-2022
9. Singeap, A.-M., Minea, H., Petrea, O., Robea, M.-A., Balmuş, I.-M., Duta, R., Iet al: Real-World Utilization of Corticosteroids in Severe Alcoholic Hepatitis: Eligibility, Response, and Outcomes. Medicina. 60, 311 (2024). https://doi.org/10.3390/medicina60020311
10. Ugwu, O. P. C., Alum, E. U., Nutritional Strategies for Rheumatoid Arthritis: Exploring Pathways to Better Management. INOSR Scientific Research. 2023; 10(1):18-26. https://doi.org/10.59298/INOSRSR/2023/3.2.47322
11. Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005
12. Boers, M.: Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider. Rheumatology (Oxford). 62, 3534–3537 (2023). https://doi.org/10.1093/rheumatology/kead309
13. Ibiam, U. A., Alum, E. U., Ugwu, O. P. C. A Comprehensive Review of Treatment Approaches and Perspectives for Management of Rheumatoid Arthritis. INOSR Scientific Research. 2023; 10(1):12-17.https://doi.org/10.59298/INOSRSR/2023/2.2.13322
14. Enríquez-Merayo, E., Cuadrado, M.J.: Steroids in Lupus: Enemies or Allies. J Clin Med. 12, 3639 (2023). https://doi.org/10.3390/jcm12113639
15. Davidson, J.E., Fu, Q., Rao, S., Magder, L.S., Petri, M.: Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. Lupus Sci Med. 5, e000237 (2018). https://doi.org/10.1136/lupus-2017-000237
16. Armin R, Fisher S I (2018). Lupus Erythematosus Cell.Arthritis & Rheumatology, 70, (7), 1101. DOI 10.1002/art.40489
17. Lombardi, C., Comberiati, P., Ridolo, E., Cottini, M., Yacoub, M.R., Casagrande, S., Riccò, M., Bottazzoli, M., Berti, A.: Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan. Drugs. 84, 661–684 (2024). https://doi.org/10.1007/s40265-024-02037-0
18. Henderson, I., Caiazzo, E., McSharry, C., Guzik, T.J., Maffia, P.: Why do some asthma patients respond poorly to glucocorticoid therapy? Pharmacol Res. 160, 105189 (2020). https://doi.org/10.1016/j.phrs.2020.105189
19. Gurnell, M., Heaney, L.G., Price, D., Menzies-Gow, A.: Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. J Intern Med. 290, 240–256 (2021). https://doi.org/10.1111/joim.13273
20. Ben Mrid, R., Bouchmaa, N., Ainani, H., El Fatimy, R., Malka, G., Mazini, L.: Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomedicine & Pharmacotherapy. 151, 113126 (2022). https://doi.org/10.1016/j.biopha.2022.113126
21. Sadiq, I.Z.: Lifestyle medicine as a modality for prevention and management of chronic diseases. J Taibah Univ Med Sci. 18, 1115–1117 (2023). https://doi.org/10.1016/j.jtumed.2023.04.001

CITE AS: Wambui Kibibi J. (2025). Steroid Treatment in Chronic Inflammatory Diseases: Analyzing Effectiveness and Patient Outcomes in Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Asthma. EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES, 6(3):110-115